Regulatory Updates, In Brief
Executive Summary
FDA approves Acorda's MS drug: FDA approved Ampyra (dalfampridine) with the novel indication of improvement in walking ability in adults with multiple sclerosis, despite a questionably meaningful responder rate and increased risk of seizure. The Jan. 22 approval is a huge win for Acorda, which took a risk developing a MS drug with an indication that had never before been studied and for which there is no target for treatment. The approval also showcases FDA's confidence that the drug will provide a clinical benefit to some patients - a point of contention during Ampyra's advisory committee review. Despite showing that Ampyra patients had statistically significant faster walking speeds than those on placebo, FDA briefing documents noted that the magnitude of improvement was small and clinical significance was uncertain (1"The Pink Sheet," Oct. 26, 2009). Adding to the uncertainty was the drug's increased risk of seizures - a widely acknowledged safety signal for 4-aminopyridine and other pyridine compounds
You may also be interested in...
FDA's Poor On-Time User Fee Performance Weighs On Renewal Debate
FDA's poor on-time performance in reviewing new drug applications will be an issue as the agency and industry negotiate the outputs expected from the next Prescription Drug User Fee Act reauthorization
FDA's Poor On-Time User Fee Performance Weighs On Renewal Debate
FDA's poor on-time performance in reviewing new drug applications will be an issue as the agency and industry negotiate the outputs expected from the next Prescription Drug User Fee Act reauthorization
REMS Reform Looks To Be Theme Of PDUFA V: Stakeholders Call For Standardization, Earlier Notice
The biggest changes that came out of the FDA Amendments Act, the last round of Prescription Drug User Fee Act reauthorization, were FDA's augmented drug safety authorities, most specifically the Risk Evaluation and Mitigation Strategy tool. Going into the next round of PDUFA negotiations, a major focus will be on improving the implementation of the REMS program